Atrium Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Atrium Therapeutics, Inc. carries a market capitalization of 139.41M, placing it among publicly traded companies globally. Its enterprise value stands at -32.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 139.41M |
| Enterprise Value | -32.15M |
Share Statistics
Atrium Therapeutics, Inc. currently has 17.11M shares outstanding.
| Shares Outstanding | 17.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.42, and the price-to-book ratio stands at 1.07.
| PE Ratio | N/A |
| PS Ratio | 6.42 |
| PB Ratio | 1.07 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | -4.61 |
| P/OCF Ratio | -4.33 |
Enterprise Valuation
| EV / Sales | 86.41 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Atrium Therapeutics, Inc. maintains a current ratio of 8.73, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.73 |
| Quick Ratio | 8.38 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -86.85 |
| Return on Assets (ROA) | -66.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 34,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Atrium Therapeutics, Inc.'s stock has declined approximately -44.74576% over the past 52 weeks. The 50-day moving average sits at 10.59, while the 200-day moving average is 12.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.74576% |
| 50-Day Moving Average | 10.59 |
| 200-Day Moving Average | 12.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Atrium Therapeutics, Inc. generated 35.84M in revenue and converted that into -93.17M in net income, yielding earnings per share of -5.45. EBITDA reached -95.71M, while operating income came in at -96.40M.
| Revenue | 35.84M |
| Gross Profit | N/A |
| Operating Income | -96.40M |
| Pretax Income | -93.32M |
| Net Income | -93.17M |
| EBITDA | -95.71M |
| EBIT | -96.40M |
| Earnings Per Share (EPS) | -5.45 |
Balance Sheet
Atrium Therapeutics, Inc. holds 263.90M in cash and equivalents against 1.68M in total debt, resulting in a net debt position of -72.33M. Total book value stands at 214.58M, with working capital of 243.54M providing operational flexibility.
| Cash & Cash Equivalents | 263.90M |
| Total Debt | 1.68M |
| Net Debt | -72.33M |
| Equity (Book Value) | 214.58M |
| Book Value Per Share | 12.54 |
| Working Capital | 243.54M |
Cash Flow
Atrium Therapeutics, Inc. produced -53.19M in operating cash flow over the past twelve months. After subtracting -3.31M in capital expenditures, free cash flow totaled -56.50M - equivalent to -3.30 per share.
| Operating Cash Flow | -53.19M |
| Capital Expenditures | -3.31M |
| Free Cash Flow | -56.50M |
| FCF Per Share | -3.30 |
Margins
Atrium Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -268.98 and net profit margin of -260.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -268.98 |
| Pretax Margin | -260.39 |
| Profit Margin | -260.00 |
| EBITDA Margin | -267.07 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -139.44 |
| FCF Yield | -21.68 |
Scores
Atrium Therapeutics, Inc. posts an Altman Z-Score of 2.09, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.09 |